[2]Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017 Jun 17;389(10087):2415-2429.[3]Chen H, Gui X, Zhou Z, et al. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients ...
[3] F. Cardoso, H.L. McArthur, P. Schmid, et al. KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine ther...
注:快速通道资格旨在精简开发和加快审查可能治疗严重或危及生命的疾病,并可能解决未满足的医疗需求的创新药物。获得这一资格的药物可以与FDA进行更频繁的互动,并有可能获得加速批准的途径。 参考来源: https://www.onclive.com/view/fda-grants-fast-track-designation-to-cfi-402257-for-er-her2-breast-cancer haoeyo...
1.https://www.targetedonc.com/view/keynote-756-of-pembrolizumab-chemotherapy-improves-pcr-in-er-her2--breast-cancer 2.Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022; 386:556-567. 3.Cortes J, Cesc...
6.Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med, 2015,Sep 27. 7.Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds ...
在ER+/HER2+乳腺癌中,细胞组成影响治疗缓解情况(ER-/HER2+细胞存在而无HER2-细胞与良好的pCR率相关)。此外,治疗后Ki67和pCR联合预测预后优于单独使用pCR。然而,需要进行更大规模的前瞻性研究来验证这些结果。 ▌参考文献: 1. The Japanese...
获得这一资格的药物可以与FDA进行更频繁的互动,并有可能获得加速批准的途径。 参考来源: https://www.onclive.com/view/fda-grants-fast-track-designation-to-cfi-402257-for-er-her2-breast-cancer haoeyou.com/qita/20230313/7344.html 「文中图片来源Pixabay,均已获版权方授权」...
The outcome of women with early breast cancer (BC) has gradually improved in the last 15years following the introduction of trastuzumab and subsequently dual blockade (trastuzumab-pertuzumab or trastuzumab followed by neratinib) [1, 2]. In the latest pivotal adjuvant trial, Aphinity, in which 60...
讲者:Komal Jhaveri;Memorial Sloan Kettering Cancer Center, New York 研究背景 ER+/HER2- 乳腺癌是占比最大的乳腺癌亚型,内分泌治疗是其标准治疗方案[3]。针对雌激素受体的靶向治疗可通过多种不同机制进行,包括直接拮抗 ER 的 ER 调节剂和降解剂,以及阻碍雌激素合成但最终可能引起编码 ERα 的基因(ESR1)发生...
《Clinical Cancer Research》于2022年8月31日在线发表了《Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer》研究评价了EndoPredict 在绝经前女性中的评估可靠性 管腔雌激素受体阳性 (ER+)、人表皮生长因子2阴性 (HER2-)乳腺癌(BC)是 BC 中最常诊...